Goodwill and Other Intangible Assets

3 Months Ended

Jul. 31, 2026

Intangible Asset, Goodwill and Other [Abstract]

Goodwill

The following table presents the changes in the carrying amount of goodwill by reportable segment and goodwill assigned to the other operating segments:


(in millions)	Cardiovascular		Neuroscience		Medical Surgical		Reportable Segments		Other Operating Segments		Total
April 24, 2026	$	8,602	$	11,777	$	19,953	$	40,332	$	2,256	$	42,587
Goodwill as a result of acquisitions	—		933		—		933		—		933
Purchase accounting adjustments	18		—		—		18		—		18
Currency translation and other	(36)		(37)		(277)		(350)		(1)		(351)
July 31, 2026	$	8,583	$	12,673	$	19,675	$	40,932	$	2,255	$	43,187

No goodwill impairment was recognized during the three months ended July 31, 2026 and July 25, 2025.

Intangible Assets

The following table presents the gross carrying amount and accumulated amortization of intangible assets:


	July 31, 2026				April 24, 2026
(in millions)	Gross Carrying Amount		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization
Definite-lived:
Customer-related	$	16,716	$	(10,824)	$	16,559	$	(10,596)
Purchased technology and patents	12,190		(8,481)		11,875		(8,319)
Trademarks and tradenames	424		(297)		422		(295)
Other	379		(135)		373		(126)
Total	$	29,709	$	(19,737)	$	29,229	$	(19,336)
Indefinite-lived:
IPR&D	$	265	$	—	$	253	$	—

The Company did not recognize any definite-lived or indefinite-lived intangible asset impairment charges during the three months ended July 31, 2026 and July 25, 2025. Due to the nature of IPR&D projects, the Company may experience future delays or failures to obtain regulatory approvals to conduct clinical trials, failures of clinical trials, delays or failures to obtain required market clearances, other failures to achieve a commercially viable product, or the discontinuation of certain projects, and as a result, may recognize impairment losses in the future.

Amortization Expense

Intangible asset amortization expense for the three months ended July 31, 2026 was $412 million. Intangible asset amortization expense for the three months ended July 25, 2025 was $459 million, including $45 million of accelerated amortization on certain intangible assets within the Cardiovascular Portfolio.